Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 8/2007

01-08-2007 | Letter to the Editor

Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia

Authors: Samart Pakakasama, Kittima Kanchanakamhaeng, Saowanee Kajanachumpol, Umaporn Udomsubpayakul, Nongnuch Sirachainan, Amnuay Thithapandha, Suradej Hongeng

Published in: Annals of Hematology | Issue 8/2007

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Ulrich CM, Robien K, McLeod HL (2003) Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3:912–920PubMedCrossRef
2.
Lecomte T, Ferraz JM, Zinzindohoue F et al (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10:5880–5888PubMedCrossRef
3.
Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100:3832–3834PubMedCrossRef
4.
National Cancer Institute (1998) Common toxicity criteria, version 2.0. National Cancer Institute, Bethesda, MD
5.
Yi P, Pogribny IP, James SJ (2002) Multiplex PCR for simultaneous detection of 677 C→T and 1298 A→C polymorphisms in methylenetetrahydrofolate reductase gene for population studies of cancer risk. Cancer Lett 181:209–213PubMedCrossRef
6.
Hongeng S, Sasanakul W, Chuansumrit A, Pakakasama S, Chattananon A, Hathirat P (2000) Frequency of thiopurine S-methyltransferase genetic variation in Thai children with acute leukemia. Med Pediatr Oncol 35:410–414CrossRef
7.
van Ede AE, Laan RF, Blom HJ et al (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:525–530
8.
Shimasaki N, Mori T, Samejima H et al (2006) Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 28:64–68PubMedCrossRef
9.
Aplenc R, Thompson J, Han P et al (2005) Methyltetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 65:2482–2487PubMedCrossRef
10.
Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T (2004) Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63:1227–1231PubMedCrossRef
11.
Herrlinger KR, Cummings JRF, Barnardo MC, Schwab M, Ahmad T, Jewell DP (2005) The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenetics Genomics 15:705–711CrossRef
12.
Cheok MH, Lugthart S, Evans WE (2006) Pharmacogenomics of acute leukemia. Ann Rev Pharmacol Toxicol 46:317–353CrossRef
13.
Stanulla M, Schaeffeler E, Flohr T et al (2005) Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 23:1485–1489CrossRef
Metadata
Title
Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia
Authors
Samart Pakakasama
Kittima Kanchanakamhaeng
Saowanee Kajanachumpol
Umaporn Udomsubpayakul
Nongnuch Sirachainan
Amnuay Thithapandha
Suradej Hongeng
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 8/2007
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-007-0274-x

Other articles of this Issue 8/2007

Annals of Hematology 8/2007 Go to the issue

Letter to the Editor

Development of a Richter syndrome with a monoclonal component from a true B-cell chronic lymphocytic leukemia (B-CLL) treated with fludarabine

Original Article

Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma

Original Article

Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation

Letter to the Editor

Paraneoplastic Sweet’s syndrome and the pathergy phenomenon

Original Article

Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas

Original Article

Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits